[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Matsakas EP, Lazaros GA, Panou FK, Karavidas AI, Papalimberi EP, Scotis ID, Zacharoulis AA: Primary pericardial fibrosarcoma presenting as "near" cardiac tamponade. Clin Cardiol; 2002 Feb;25(2):83-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A partial pericardiectomy was performed to relieve the patient's symptoms, and histologic examination of a biopsy specimen showed features of a malignant, spindle cell, mesenchymal neoplasm.
  • The patient underwent surgical treatment during which the tumor was found to infiltrate the anterior surface of the right ventricle.
  • Histologically, the tumor was identified as a high-grade fibrosarcoma, and additional chemotherapy was given.
  • [MeSH-major] Cardiac Tamponade / etiology. Fibrosarcoma / diagnosis. Heart Neoplasms / diagnosis. Pericardium
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11841156.001).
  • [ISSN] 0160-9289
  • [Journal-full-title] Clinical cardiology
  • [ISO-abbreviation] Clin Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Patel T, Bansal R, Trivedi P, Modi L, Shah MJ: Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):482-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
  • A 25 year old woman, who had undergone chemotherapy, partial excision of tumor followed by radiotherapy of sarcomatoid mesothelioma of the pleura, presented three months later with painless widespread subcutaneous nodules.
  • FNAC of these nodules reveled pleomorphic malignant spindle shaped cell with epithelioid morphology.
  • It is essential to differentiate neoplasm metastatic to the skin and subcutis from primary and benign lesions of the same region.
  • FNAC is accurate and efficient, in conjugation with clinical history, and it also prevents surgical biopsy in the diagnosis of metastatic subcutaneous lesion.
  • To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
  • [MeSH-major] Mesothelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pleural Neoplasms. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Subcutaneous Tissue

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366102.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Berrebi O, Steiner C, Keller A, Rougemont AL, Ratib O: F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones. Clin Nucl Med; 2008 Jul;33(7):469-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 fluorodeoxyglucose (FDG) PET in the diagnosis of malignant transformation of fibrous dysplasia in the pelvic bones.
  • Fibrous dysplasia (FD) is a benign dysplastic pathology of bone-forming mesenchymal cells, resulting in replacement of trabecular bone by abnormal fibrous and immature osseous tissue.
  • We report the case of a 59-year-old woman with monostotic FD of the left ischium, known for over 30 years, who developed sarcomatous transformation in a low-grade spindle-cell sarcoma.
  • The value of F-18 fluorodeoxyglucose positron emission tomography in the early diagnosis of malignant transformation, the evaluation of distant metastasis, as well as monitoring the efficacy of chemotherapy are discussed.
  • [MeSH-major] Fibrous Dysplasia of Bone / diagnosis. Fibrous Dysplasia of Bone / radionuclide imaging. Fluorodeoxyglucose F18. Pelvis / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Bone and Bones / radionuclide imaging. Cell Proliferation. Cell Transformation, Neoplastic. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography / methods. Sarcoma / diagnosis

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580231.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Databank-accession-numbers] OMIM/ 174800
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC: Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblasts. Cancer Biol Ther; 2004 Dec;3(12):1236-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bin1 expression is often attenuated during tumor progression and Bin1 splice isoforms that localize to the nucleus display tumor suppressor properties.
  • While these properties may reflect the ability of these isoforms to interact with and suppress the cell transforming activity of c-Myc, the effects of Bin1 deletion on the oncogenicity of c-myc or other transforming genes has not been gauged directly.
  • Specifically, Bin1 loss accentuated the spindle morphology of transformed cells, increased anchorage-independent proliferation, and promoted tumor formation in syngeneic hosts.
  • Although some Bin1 splice isoforms associate with endocytotic complexes the effects of Bin1 loss were not correlated with a generalized defect in receptor-mediated endocytosis.
  • However, Bin1 loss increased sensitivity to paclitaxel, a drug that can affect endocytotic trafficking by disrupting microtubule dynamics.
  • In E1A?transformed MEFs, Bin1 loss reduced the susceptibility to apoptosis triggered by tumor necrosis factor-alpha, an effect that was associated with precocious nuclear trafficking of NF-kappaB.
  • These findings offer a novel line of support for the hypothesized role of Bin1 in limiting malignant growth, possibly as a negative modifier or anti-progression gene.

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611650.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100123; United States / NCI NIH HHS / CA / CA82222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adenovirus E1A Proteins; 0 / Antineoplastic Agents, Phytogenic; 0 / Bin1 protein, mouse; 0 / NF-kappa B; 0 / Nerve Tissue Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Proteins; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, Mayerhofer K: Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report. Wien Klin Wochenschr; 2003 Mar 31;115(5-6):191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth-muscle neoplasm with fewer than 30 documented cases worldwide.
  • CASE REPORT: The patient, a 71-year-old woman, presented with a history of lower abdominal pain and a palpable mass in the lower abdomen.
  • Surgical exploration revealed a large left adnexal mass that had developed from the left ovary and infiltrated one part of the omentum adherent to the left adnexa.
  • Microscopically the left adnexal tumor consisted of spindle cells arranged in smooth-muscle bundles and fascicles.
  • The tumor was characterized by high cellularity and nuclear polymorphism, as well as patchy necrosis and large areas of hemorrhage.
  • The tumor appeared encapsulated, and the capsule was partially disrupted by tumor cells.
  • Immunohistochemically, the tumor showed a strong staining reaction for muscle actin, alpha-SMA and neuron-specific enolase, and also a weak reaction for vimentin.
  • According to the FIGO staging system for ovarian cancer, the tumor was classified as a primary ovarian leiomyosarcoma stage III C, and the patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • Two days after the third cycle of cisplatin/ifosfamid she developed an apoplexy spontaneously and chemotherapy was therefore discontinued.
  • In order to understand more about the nature and the behaviour of this highly malignant neoplasm and to be able to improve the treatment, the prognostic value of bcl-2 has to be investigated in additional studies.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Ovariectomy. Ovary / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Jul-Sep;39(3):151-3 [8051647.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):116-20 [3308653.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1003-7 [7734290.001]
  • [Cites] Exp Cell Res. 1991 Aug;195(2):277-83 [2070813.001]
  • [Cites] Gynecol Oncol. 1993 Mar;48(3):389-93 [8462904.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1941-52 [8952529.001]
  • [Cites] N Engl J Med. 1993 Sep 2;329(10):690-4 [8393963.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):941-5 [1929791.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1658-64 [10408415.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1097-8 [1648446.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(3):172-3 [10410877.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):162-5 [10792777.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Dec;26(6):401-7 [11152324.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):499-504 [8133533.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):293-9 [8989276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8 [3523487.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):745-8 [12445253.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):257-61 [9641226.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):519-25 [9299270.001]
  • [Cites] Gynecol Oncol. 1987 Feb;26(2):183-92 [3643159.001]
  • [Cites] Am J Obstet Gynecol. 1972 Jan 15;112(2):183-91 [4109398.001]
  • (PMID = 12741081.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


6. Magrini E, Pragliola A, Farnedi A, Betts CM, Cocchi R, Foschini MP: Cytogenetic analysis of myoepithelial cell carcinoma of salivary gland. Virchows Arch; 2004 Jan;444(1):82-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of myoepithelial cell carcinoma of salivary gland.
  • Myoepithelial cell carcinoma (MCC) of the salivary gland is a rare entity.
  • The patient was a 53-year-old man, with a rapidly growing lesion of the palate.
  • Despite complete surgical excision, radio- and chemotherapy, the lesion rapidly harboured local and distant metastases leading to the death of the patient, 4 months after the diagnosis.
  • On histological and ultrastructural examination, the primary tumour and the related metastases were composed of oval and spindle cells, with features of myoepithelial cell differentiation reported in the literature.
  • Cytogenetic analysis showed a composite karyotype in the primary tumour: 45-46,XY, +3[cp3]/ 44-45,XY, -17[cp4]/ 46,XY[5].
  • Our cytogenetic data differ from those described in benign or slowly growing salivary gland tumours showing myoepithelial cell differentiation.
  • It is suggested that highly aggressive tumours might follow a different pathway of malignant transformation.
  • [MeSH-minor] Calcium-Binding Proteins / analysis. Cell Differentiation. DNA-Binding Proteins. Fatal Outcome. Genes, Tumor Suppressor. Humans. Karyotyping. Keratins / analysis. Lymphatic Metastasis / pathology. Male. Microfilament Proteins. Middle Aged. Neoplasm Metastasis / pathology. Palate, Hard. Phosphoproteins / analysis. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1986 Dec;23(4):305-13 [3022913.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Virchows Arch. 1997 Apr;430(4):339-42 [9134046.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):49-53 [10459346.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):66-9 [9973962.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2314-9 [9191518.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):161-7 [11135432.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):761-74 [10843278.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • (PMID = 14994730.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / DNA-Binding Proteins; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / calponin; 68238-35-7 / Keratins
  •  go-up   go-down


7. Kenan S, Ginat DT, Steiner GC: Dedifferentiated high-grade osteosarcoma originating from low-grade central osteosarcoma of the fibula. Skeletal Radiol; 2007 Apr;36(4):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low grade central osteosarcoma is a distinct, rare low grade malignant neoplasm characterized histologically by a spindle cell proliferation associated with trabecular bone formation.
  • This tumor usually carries a good prognosis.
  • However, it has the potential to recur, dedifferentiate, and metastasize subsequent to surgical treatment.
  • Following biopsy the patient received 3 months of chemotherapy at a different institution.
  • X-rays indicated a very aggressive tumor in the diaphysis of the proximal fibula, MRI revealed soft tissue involvement.
  • The tumor and surrounding soft-tissues were excised en bloc at our institution.
  • The two histological components of the tumor were sharply delineated from one another.
  • No chemotherapy effect was appreciated histologically or clinically.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fibula / pathology. Lung Neoplasms / secondary. Osteosarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging / methods


8. Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, Liu TP: Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol; 2005 Sep 1;91(3):185-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.
  • They are composed of a benign epithelial component and a cellular, spindle cell stroma forming a leaf-like structure.
  • No one morphologic finding is reliable in predicting the clinical behavior of the tumor.
  • Clinical data analyzed included age, presenting symptoms and signs, tumor size, location, type of surgery, time to recurrence, and metastasis.
  • The pathologic diagnoses included 131 benign, 12 borderline, and 29 malignant lesions.
  • The initial diagnosis of all 19 recurrent tumors were benign.
  • Stromal cellularity, stromal overgrowth, stromal atypia, mitotic activity, tumor margin, and heterologous stromal elements were significantly correlated with metastases (P = 0.032, 0.00008, 0.000002, 0.004, 0.005, and 0.046, respectively).
  • The role of adjuvant radiotherapy and chemotherapy remains to be defined.
  • Local excision, wide excision, or mastectomy with negative surgical margins yielded high local control rates (88.7%, 88.2%, and 100%, respectively), but local excision was associated with a relatively high percentage of positive surgical margins (18.3%).
  • The reasons for these procedures included a diagnosis of malignancy on frozen section or because the tumors were so large, they were assumed to be carcinomas.
  • Fifteen patients in our series had tumors with infiltrating tumor margin, severe stromal overgrowth, atypia, and cellularity.
  • CONCLUSIONS: Wide excision with a clear margin may be the preferable initial therapy, even for malignant PTs.
  • Patients have tumors with infiltrating tumor margin, severe stromal overgrowth, atypia, and cellularity are at high risk for metastases.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy / methods. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Taiwan / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118768.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Li CQ, Guo ZM, Liu WW, Zhang Q, Yang AK, Yang L: [Clinical analysis of myoepithelial carcinoma of head and neck]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Feb;45(2):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate clinical feature, diagnosis, treatment and prognosis of myoepithelial carcinoma (MC) in the head and neck.
  • METHODS: Clinical data of 11 patients which were confirmed by pathology and immunohistochemistry in Cancer Center, Sun Yat-sen University from Jan.
  • The median age at diagnosis was 37 years (range: 14 - 60 years).
  • RESULTS: All cases were operated, 4 underwent surgery alone, 2 underwent surgery plus adjuvant radiotherapy, 2 received surgery plus adjuvant chemotherapy, 3 underwent surgery plus adjuvant chemoradiation.
  • There was spindle cell type in 5 cases, clear cell type, plasmacytoid cell type in 2 cases, epithelioid cell type, mixed type in 1 case.
  • The median follow-up time was 40 months.
  • AS to the last follow-up time, 8 patients died.
  • CONCLUSIONS: The characteristics of the tumor were rapidly enlarging, invading the surrounding regions, high rates of lymph node metastasis, high rates of distance metastasis.
  • MC was a sort of malignant tumor.
  • Chemotherapy and radiotherapy may be effective after operation.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398508.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Ishihara S, Honda Y, Asato T, Nonaka M, Nakagawa S, Hirashima K, Hayashi N, Baba H, Iyama K: Interdigitating dendritic cell sarcoma of the ileum recurred in multiple lymph nodes and duodenum three years after operation without chemotherapy. Pathol Res Pract; 2010 Jul 15;206(7):514-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdigitating dendritic cell sarcoma of the ileum recurred in multiple lymph nodes and duodenum three years after operation without chemotherapy.
  • Neoplasms derived from interdigitating dendritic cell are extremely rare.
  • Here we describe a case of a 47-year-old man with interdigitating dendritic cell sarcoma (IDCS) in the ileum.
  • The ileal tumor, measuring 2cm, was detected and resected with regional lymphadenectomy.
  • At that time, a pathologic diagnosis of malignant peripheral nerve sheath tumor was made.
  • The patient, who was not treated with chemotherapy, showed no signs of recurrence.
  • Oval to spindle-shaped atypical cells, which resembled ileal tumor cells, infiltrated into the lymph node and duodenum.
  • Based on the histologic and immunohistochemical analysis, the histopathologic diagnosis of IDCS was confirmed.
  • To our knowledge, five cases of IDCS arising in the intestinal tract have been reported to date, and only one case, treated with both surgery and chemotherapy, led to remission.
  • This is the first case that has a comparatively favorable prognosis without chemotherapy after surgery.
  • [MeSH-major] Dendritic Cell Sarcoma, Interdigitating / pathology. Duodenal Neoplasms / pathology. Ileal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Diagnostic Errors. Digestive System Surgical Procedures. Humans. Immunohistochemistry. Male. Middle Aged. Nerve Sheath Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399026.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Rosell R, Taron M, Camps C, López-Vivanco G: Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc); 2003 Oct;39(10):775-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of genetic markers on survival in non-small cell lung cancer.
  • Cisplatin or carboplatin is commonly used with gemcitabine, docetaxel, paclitaxel or vinorelbine as chemotherapy doublets in the treatment of advanced non-small cell lung cancer.
  • This lack of evidence for improvement in survival with any chemotherapy regimen has created a tabula rasa in which no more large randomized trials should be conducted with out including a genetic analysis.
  • Patients see survival as their major concern, and other considerations, such as cost of treatment and qualify of life, are relegated to lower positions.
  • For a long time, ERCC1 mRNA levels have been known to correlate with DNA repair capacity in various tissues.
  • Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia.
  • Overexpression of ERCC1 correlates with poor survival gemcitabine/cisplatin-treated non-small cell lung cancer patients.
  • An ongoing customized ERCC1-based chemotherapy trial has been established on this knowledge.
  • At the preclinical level, ERCC1 and XPD mRNA expression correlate with each other, and overexpression of XPD causes selective cisplatin resistance in human tumor cell lines.
  • In our experience, time to disease progression is significantly higher in gemcitabine/cisplatin-treated patients with the Lys751Gln genotype (9.6 months) than in those with the Lys751Lys genotype (4.2 months; p = 0.03).
  • This highlights the possibilities of individually tailored chemotherapy.
  • Patients with Lys751Lys had a longer time to progression.
  • At least 50% of non-small cell lung cancer patients harbor Lys751Lys and can benefit from docetaxel/ cisplatin treatment.
  • Genes involved in spindle formation, centrosome functions and mRNA transport along the microtubule tracks should provide further information on potential markers of docetaxel resistance.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / mortality. DNA Helicases. DNA-Binding Proteins. Deoxycytidine / analogs & derivatives. Lung Neoplasms / genetics. Lung Neoplasms / mortality. Transcription Factors
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cisplatin / pharmacology. Cisplatin / therapeutic use. Clinical Trials as Topic. DNA Adducts / metabolism. DNA Repair. Drug Resistance, Neoplasm / genetics. Genetic Markers. Humans. Polymorphism, Genetic. Proteins / genetics. Ribonucleotide Reductases / genetics. Survival Rate. Xeroderma Pigmentosum Group D Protein

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14668933.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / Proteins; 0 / Transcription Factors; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 54
  •  go-up   go-down


12. de la Roza G, Naqvi A, Clark K: Gastrointestinal stromal tumors presenting as a prostatic mass. Can J Urol; 2009 Feb;16(1):4502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumors (GISTs) are a rare and heterogeneous group of spindle cell neoplasms that have also been reported outside of gastrointestinal (GI) tract.
  • These tumors are characterized by somatic mutations of c-KIT (CD117), a proto-oncogene that encodes a receptor tyrosine kinase normally expressed in the interstitial cell of Cajal that control the GI smooth muscle peristalsis, and an exquisite sensitivity to the action of the tyrokinase inhibitor imatinib mesylate (STI571; Gleevec).
  • We report two cases of gastrointestinal stromal tumor identified on prostatic biopsies, where a primary prostatic sarcoma was considered in the differential diagnosis.
  • In one of the cases, there was extensive local disease involving prostate, rectum, and pelvic wall, as well as metastatic disease that quickly lead to the patient's death despite aggressive treatment with imatinib mesylate and conventional chemotherapy.
  • In the other case, the tumor was mostly confined to the rectum but also focally extended into the prostate capsule.
  • In both cases, tissue samples from prostate and the rectum showed a malignant spindle cell neoplasm, which was positive for CD117 (c-kit).
  • Given their unique clinical management, gastrointestinal stromal tumors should be considered in the differential diagnosis of spindle cell lesions on prostatic needle biopsies and CD117 should be added to the immunohistochemical panel in the work-up of such lesions to avoid misinterpreting them as primary prostatic neoplasms.


13. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We now report a case of meningioangiomatosis-associated meningioma with atypical and clear cell variant.
  • He had no stigmata of neurofibromatosis type 2.
  • Microscopically, parts of lesions were atypical and clear cell meningioma corresponding to WHO grade II.
  • However, the spindle cells in meningioangiomatosis area were negative for EMA with low MIB-1 index of up to 1%.
  • The diagnosis of atypical meningioma associated with sporadic meningioangiomatosis was made.
  • To our knowledge, this is the first case of a meningioangiomatosis-associated meningioma with atypical and clear cell variant component to be described.
  • The patient had been followed-up for 11 months without adjuvant radiotherapy or chemotherapy.
  • No tumor recurrence was found during this period.
  • We suggest that postoperative radiotherapy or chemotherapy should be given careful consideration to avoid over-treatment due to erroneously interpret as malignant meningioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


14. Radhika S, Bakshi A, Rajwanshi A, Nijhawan R, Das A, Kakkar N, Joshi K, Marwaha RK, Rao KL: Cytopathology of uncommon malignant renal neoplasms in the pediatric age group. Diagn Cytopathol; 2005 May;32(5):281-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of uncommon malignant renal neoplasms in the pediatric age group.
  • Malignant renal neoplasms are common solid tumors in pediatric oncology practice.
  • These include the common Wilms' tumor/nephroblastoma and the uncommon neoplasms such as clear-cell sarcoma of the kidney (CCSK), rhabdoid tumor, renal-cell carcinoma, and others.
  • Aspirates from Wilms' tumor, which are mesenchyme predominant, show clusters of spindle cells associated with the matrix material.
  • CCSK, classic subtype, is characterized by round to oval cells arranged perivascularly and also in sheets and clusters intimately associated with a metachromatic matrix mucopolysaccharide material better appreciated in May-Grunwald-Giemsa (MGG)-stained smears.
  • Spindle-cell pattern of CCSK is difficult to diagnose on aspiration cytology.
  • Renal-cell carcinoma of childhood shows similar cytological features as its adult counterpart.
  • Rhabdoid tumor of the kidney is characterized by a monomorphic population of cells with abundant cytoplasm, eccentric nuclei with prominent nucleoli.
  • Intrarenal yolk sac tumor is a rare neoplasm and shows severely pleomorphic cells on aspiration.
  • Further, non-Wilms' renal malignant neoplasms must be distinguished from the common Wilms' tumor so that appropriate chemotherapy protocols may be instituted in cases where the tumor is in an advanced stage of malignancy.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Endodermal Sinus Tumor / pathology. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adolescent. Cell Nucleus / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Staining and Labeling. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830360.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Danker K, Reutter W, Semini G: Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Br J Pharmacol; 2010 May;160(1):36-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell expansion and metastasis are considered hallmarks of tumour progression.
  • Therefore, efforts have been made to develop novel anti-cancer drugs that inhibit both the proliferation and the motility of tumour cells.
  • Synthetic alkylphospholipids, compounds with aliphatic side chains that are ether linked to a glycerol backbone, are structurally derived from platelet-activating factor and represent a new class of drugs with anti-proliferative properties in tumour cells.
  • These compounds do not interfere with the DNA or mitotic spindle apparatus of the cell.
  • Instead, they are incorporated into cell membranes, where they accumulate and interfere with lipid metabolism and lipid-dependent signalling pathways.
  • Recently, it has been shown that the most commonly studied alkylphospholipids inhibit proliferation by inducing apoptosis in malignant cells while leaving normal cells unaffected.
  • Members of this subfamily also exhibit anti-proliferative capacity and modulate the cell adhesion, differentiation, and migration of tumour cells.
  • Apart from its anti-proliferative effect, Ino-C2-PAF strongly reduces cell motility via its inhibitory effect on the phosphorylation of the cytosolic tyrosine kinases FAK and Src.
  • Signalling pathways under the control of the FAK/Src complex are normally required for both migration and proliferation and play a prominent role in tumour progression.
  • We intend to highlight the potential of glycosidated phospholipids, especially Ino-C2-PAF, as a promising new group of drugs for the treatment of hyperproliferative and migration-based skin diseases.
  • [MeSH-minor] Animals. Cell Membrane / metabolism. Cell Movement / drug effects. Cell Proliferation / drug effects. Humans. Inositol / adverse effects. Inositol / analogs & derivatives. Inositol / pharmacology. Molecular Structure. Neoplasm Metastasis. Neoplasms / drug therapy. Neoplasms / pathology. Platelet Activating Factor / adverse effects. Platelet Activating Factor / analogs & derivatives. Platelet Activating Factor / pharmacology. Signal Transduction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] FASEB J. 2001 Aug;15(10):1739-44 [11481221.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3860-3 [11739199.001]
  • [Cites] Chem Rev. 2001 Aug;101(8):2449-76 [11749383.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33857-63 [12105199.001]
  • [Cites] Eur J Biochem. 2002 Sep;269(18):4649-55 [12230578.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Curr Drug Metab. 2002 Oct;3(5):491-525 [12369895.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39541-7 [12183451.001]
  • [Cites] Nature. 2002 Dec 12;420(6916):629-35 [12478284.001]
  • [Cites] Anticancer Drugs. 2003 Feb;14(2):167-73 [12569304.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2291-5 [12894505.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1093-103 [14617782.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):353-65 [15289504.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5242-52 [15297428.001]
  • [Cites] Biochim Biophys Acta. 1965 Oct 4;106(2):348-56 [5867695.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1969;36(1):117-28 [4980286.001]
  • [Cites] Int Arch Allergy Appl Immunol. 1973;45(1):133-5 [4353764.001]
  • [Cites] Cancer Res. 1978 Feb;38(2):339-44 [620405.001]
  • [Cites] Cancer Res. 1978 Nov;38(11 Pt 1):3894-9 [279399.001]
  • [Cites] Nature. 1979 Jun 28;279(5716):799-800 [377104.001]
  • [Cites] Blood. 1979 Aug;54(2):519-23 [287519.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4681-6 [498095.001]
  • [Cites] J Biol Chem. 1986 Jul 15;261(20):9128-32 [3087989.001]
  • [Cites] J Cell Biol. 1988 Mar;106(3):761-71 [2450098.001]
  • [Cites] Lipids. 1987 Nov;22(11):842-6 [3444375.001]
  • [Cites] Lipids. 1987 Nov;22(11):851-5 [3444377.001]
  • [Cites] Lipids. 1987 Nov;22(11):862-7 [3444379.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Apr 29;152(2):491-6 [2452631.001]
  • [Cites] Exp Mol Pathol. 1989 Feb;50(1):69-83 [2920821.001]
  • [Cites] Onkologie. 1988 Dec;11(6):295-6 [3071766.001]
  • [Cites] Chem Immunol. 1990;49:206-35 [2190582.001]
  • [Cites] Hautarzt. 1990 May;41(5):256-61 [2197251.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17381-4 [2170377.001]
  • [Cites] Onkologie. 1990 Aug;13(4):295-300 [2234783.001]
  • [Cites] Cancer Treat Rev. 1990 Sep;17(2-3):243-6 [2272039.001]
  • [Cites] Ann N Y Acad Sci. 1990;603:246-54; discussion 254-5 [2291524.001]
  • [Cites] Annu Rev Biochem. 1991;60:73-99 [1883207.001]
  • [Cites] Anticancer Res. 1991 May-Jun;11(3):1285-92 [1888162.001]
  • [Cites] J Immunol. 1992 Jan 15;148(2):514-23 [1309560.001]
  • [Cites] Eur J Cancer. 1991;27(12):1650-3 [1782078.001]
  • [Cites] J Biol Chem. 1992 Apr 5;267(10):6719-24 [1313020.001]
  • [Cites] Prog Exp Tumor Res. 1992;34:153-9 [1438798.001]
  • [Cites] Prog Exp Tumor Res. 1992;34:160-9 [1438799.001]
  • [Cites] Prog Exp Tumor Res. 1992;34:33-46 [1438801.001]
  • [Cites] Int J Cancer. 1993 Jan 2;53(1):124-30 [8416196.001]
  • [Cites] Biochim Biophys Acta. 1993 Mar 14;1146(2):294-300 [8452863.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Apr 30;192(2):603-9 [8484770.001]
  • [Cites] Biochem Pharmacol. 1993 Jun 22;45(12):2435-9 [8328981.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1680-8 [7509446.001]
  • [Cites] Eur J Cancer. 1994;30A(4):509-15 [8018410.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 1):1594-8 [7933213.001]
  • [Cites] Biochem J. 1995 Feb 1;305 ( Pt 3):689-705 [7848265.001]
  • [Cites] J Dermatol. 1994 Nov;21(11):821-8 [7852642.001]
  • [Cites] J Biol Chem. 1995 Mar 31;270(13):7757-64 [7706325.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11612-8 [7744800.001]
  • [Cites] J Cell Biol. 1995 Sep;130(5):1181-7 [7657702.001]
  • [Cites] Med Res Rev. 1995 May;15(3):157-223 [7658750.001]
  • [Cites] J Med Chem. 1996 Aug 16;39(17):3241-7 [8765506.001]
  • [Cites] Br J Dermatol. 1996 Nov;135(5):696-703 [8977667.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1320-8 [9102220.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 5;1389(1):1-12 [9443598.001]
  • [Cites] J Biol Chem. 1998 Jan 23;273(4):2169-73 [9442058.001]
  • [Cites] Exp Cell Res. 1998 Mar 15;239(2):326-31 [9521850.001]
  • [Cites] Mol Pharmacol. 1998 Apr;53(4):602-12 [9547349.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):11025-31 [9556584.001]
  • [Cites] Anticancer Res. 1998 Jan-Feb;18(1A):465-70 [9568121.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2457-63 [10344758.001]
  • [Cites] Br J Pharmacol. 1999 Jun;127(4):813-25 [10433487.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4808-15 [10519389.001]
  • [Cites] Eur J Cancer. 2004 Nov;40(17):2560-91 [15541959.001]
  • [Cites] Curr Med Chem. 2004 Dec;11(24):3163-84 [15579006.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68 [15688067.001]
  • [Cites] J Cell Sci. 2005 Mar 15;118(Pt 6):1233-43 [15741229.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2422-32 [15781658.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7429-35 [16103096.001]
  • [Cites] J Med Chem. 2005 Oct 20;48(21):6750-5 [16220990.001]
  • [Cites] J Cell Sci. 2005 Nov 1;118(Pt 21):4917-9 [16254237.001]
  • [Cites] Chembiochem. 2006 Mar;7(3):441-9 [16453359.001]
  • [Cites] FEBS Lett. 2006 May 1;580(10):2471-6 [16638573.001]
  • [Cites] Blood. 2006 May 15;107(10):4053-62 [16418332.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1559-70 [16818515.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):795-805 [16936256.001]
  • [Cites] Biochem J. 2007 Jan 15;401(2):541-9 [17049047.001]
  • [Cites] Blood. 2007 Jan 15;109(2):711-9 [17003375.001]
  • [Cites] J Cell Biol. 2007 Feb 26;176(5):667-80 [17325207.001]
  • [Cites] Cancer Treat Rev. 2007 Apr;33(2):191-202 [17287087.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):281-94 [17384583.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2029-38 [17604333.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):123-8 [18097585.001]
  • [Cites] Leukemia. 2008 Jan;22(1):147-60 [17928881.001]
  • [Cites] Asia Pac J Clin Nutr. 2008;17 Suppl 1:204-7 [18296338.001]
  • [Cites] Curr Pharm Des. 2008;14(21):2061-74 [18691116.001]
  • [Cites] J Phys Chem B. 2008 Sep 18;112(37):11643-54 [18712919.001]
  • [Cites] IUBMB Life. 2008 Oct;60(10):661-8 [18720418.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):64-9 [18687514.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9394-403 [19010914.001]
  • [Cites] Hum Genomics. 2008 Sep;3(1):53-70 [19129090.001]
  • [Cites] Curr Oncol Rep. 2009 Mar;11(2):102-10 [19216841.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Mar 20;380(4):780-4 [19338752.001]
  • [Cites] PLoS One. 2009;4(4):e5044 [19352436.001]
  • [Cites] J Pharmacol Exp Ther. 2009 May;329(2):439-49 [19244550.001]
  • [Cites] PLoS Biol. 2009 Jun 2;7(6):e1000121 [19492080.001]
  • [Cites] Inflamm Allergy Drug Targets. 2009 Jul;8(3):182-90 [19601878.001]
  • [Cites] Pharmacotherapy. 2009 Aug;29(8):954-65 [19637949.001]
  • [Cites] FEBS Lett. 1991 Aug 19;288(1-2):129-32 [1879545.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;44 Suppl:S29-30 [10602908.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):208-18 [10738248.001]
  • [Cites] Biol Chem. 2000 Feb;381(2):135-44 [10746745.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):807-69 [11274345.001]
  • (PMID = 20331609.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glycosides; 0 / Phospholipids; 0 / Platelet Activating Factor; 4L6452S749 / Inositol
  • [Number-of-references] 116
  • [Other-IDs] NLM/ PMC2860204
  •  go-up   go-down


16. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • Anderson Cancer Center in a 16-year period (1990 to 2005).
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • Three cases had also spindle cells.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


17. Mohanty SK, Balani JP, Parwani AV: Pleomorphic leiomyosarcoma of the adrenal gland: case report and review of the literature. Urology; 2007 Sep;70(3):591.e5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed a large heterogeneous left adrenal mass abutting the renal vessels.
  • The adrenal mass was resected and histopathologic examination revealed a highly pleomorphic malignant spindle cell neoplasm diffusely infiltrating the adrenal parenchyma with an immunoprofile consistent with that of a leiomyosarcoma.
  • [MeSH-minor] Abdominal Pain / etiology. Adrenalectomy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Leiomyoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Neoplasms, Second Primary / pathology. Nephrectomy. Radiotherapy, Adjuvant. Taxoids / administration & dosage. Thrombophlebitis / etiology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905130.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 14
  •  go-up   go-down


18. Raveglia F, Mezzetti M, Panigalli T, Furia S, Giuliani L, Conforti S, Meda S: Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg; 2004 Nov;78(5):1742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pleomorphic carcinoma is a rare epithelial malignant tumor.
  • Pulmonary pleomorphic carcinoma was introduced by the 1999 World Health Organization classification as a new peculiar type of lung carcinoma showing concurrent malignant epithelial and sarcomatoid spindle cell elements.
  • My colleagues and I report a series of patients surgically treated for pulmonary pleomorphic carcinoma to describe our experience with this malignant neoplasm.
  • Histologic diagnosis was established by using light microscopic examination and immunohistochemistry.
  • RESULTS: We postoperatively diagnosed 20 cases of pleomorphic carcinoma: 14 cases were exclusively spindle and giant-cell carcinomas, 2 cases were spindle and giant-cell carcinoma combined with adenocarcinoma, 2 were combined with squamous cell carcinoma, and 2 were combined with large cell carcinoma.
  • CONCLUSIONS: The prognosis of patients with pleomorphic carcinoma was poor, despite surgery and adjuvant chemotherapy, because of early relapse of disease.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Giant Cell / mortality. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / surgery. Cell Differentiation. Disease-Free Survival. Female. Follow-Up Studies. Humans. Life Tables. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for pleomorphic carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15511465.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 20
  •  go-up   go-down


19. Nakatani H, Akimori T, Takezaki Y, Hanazaki K: Vascular endothelial growth factors and their receptors in the novel human cell line, HN-Eso-1, established from esophageal spindle cell carcinoma. J Med Invest; 2010 Aug;57(3-4):232-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factors and their receptors in the novel human cell line, HN-Eso-1, established from esophageal spindle cell carcinoma.
  • Human carcinosarcomas of esophagus are uncommon malignant neoplasms that are composed both carcinomatous and sarcomatous components.
  • We established a novel cell line, HN-Eso-1, from the metastatic esophageal spindle cell carcinoma (so-called carcinosarcoma).
  • Cisplatin reduced the cell viability of HN-Eso-1 cells and VEGF attenuated its effect.
  • These results suggest that expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-1, and VEGFR-2 are involved in the cell's autocrine system and that VEGF protected these cells from the anti-tumor agent.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Base Sequence. Carcinosarcoma / drug therapy. Carcinosarcoma / genetics. Carcinosarcoma / metabolism. Carcinosarcoma / pathology. Cell Culture Techniques. Cell Line, Tumor. Cisplatin / pharmacology. DNA Primers / genetics. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Vascular Endothelial Growth Factor C / genetics. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / genetics. Vascular Endothelial Growth Factor D / metabolism. Vascular Endothelial Growth Factor Receptor-1 / genetics. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / genetics. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847522.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFA protein, human; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Tanguay C, Harvey I, Houde M, Srigley JR, Têtu B: Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol; 2003 May;16(5):512-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.
  • Leiomyosarcoma of urinary bladder is rare, although it is the most common mesenchymal tumor in adults.
  • We report two cases of this tumor following cyclophosphamide therapy.
  • He presented with painless hematuria, and the initial biopsy of the bladder tumor revealed a malignant spindle cell neoplasm.
  • A final diagnosis of leiomyosarcoma was made on radical cystoprostatectomy.
  • He also presented with painless hematuria, and a bladder tumor was resected transurethrally and diagnosed as leiomyosarcoma.
  • Cyclophosphamide, when used for a neoplastic or non-neoplastic condition, is associated with an increased risk of developing bladder cancer.
  • A review of the literature shows an increased proportion of squamous cell carcinomas and sarcomas, especially leiomyosarcomas in cyclophosphamide exposed patients.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulomatosis with Polyangiitis / complications. Granulomatosis with Polyangiitis / drug therapy. Humans. Male. Middle Aged. Neoplasms, Second Primary. Retinoblastoma / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12748258.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


21. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Herein is reported a case of a 74-year-old woman with a giant malignant SFT in the pelvis.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for CD34, CD99, and bcl-2.
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • The patient received systemic and the intra-arterial chemotherapy followed by whole pelvic radiation therapy (50 Gy).
  • Initial chemotherapies failed to control the tumor.
  • Afterwards, improvement was observed radiologically and pathologically in the 12 months' follow up after the radiation therapy.
  • This is the first report related to therapeutic remarks on advanced malignant SFT.
  • [MeSH-major] Carcinoma / radiotherapy. Neoplasms, Fibrous Tissue / radiotherapy. Pelvic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


22. Arenas LF, Fontes DA, Pereira EM, Hering FL: Sarcomatoid carcinoma with osseous differentiation in the bladder. Int Braz J Urol; 2006 Sep-Oct;32(5):563-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Bladder sarcomatoid carcinoma is a very rare variant of transitional cell carcinoma.
  • With disputed nomenclature, the tumor has been described previously under a variety of names such as sarcomatoid carcinoma, pseudosarcoma, malignant mixed mesodermal/Müllerian tumor, metaplastic carcinoma and spindle cell carcinoma.
  • This malignancy represents 0.3% of all bladder tumors and has an aggressive behavior yielding a poor prognosis despite radio and chemotherapy.
  • CASE REPORT: An 81 y/o man presented with a transitional cell carcinoma and underwent a transurethral resection.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Aged, 80 and over. BCG Vaccine / therapeutic use. Cystectomy. Fatal Outcome. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local / surgery. Prostatectomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081326.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


23. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Primary sarcoma occurring in breast is rare and comprises 0.5-1% of all breast neoplasm.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Two patients received chemotherapy.
  • After a mean follow-up time of 34.5 months (median 25 months), eight patients failed.
  • Surgical treatment should consist of at least simple mastectomy.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ulamec M, Soldo-Belić A, Vucić M, Buljan M, Kruslin B, Tomas D: Melanoma with second myxoid stromal changes after personally applied prolonged phototherapy. Am J Dermatopathol; 2008 Apr;30(2):185-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most malignant melanomas are easily diagnosed; however, melanoma is also one of the lesions most frequently reported to mimic other tumors.
  • Clinically, the lesion was unevenly pigmented, ulcerated, covered with hemorrhagic crust, and measuring 3.5 cm in greatest dimension, with a satellite nodule.
  • Histologically, the primary tumor and metastases were composed of nests and pseudotubular formations of polygonal, spindle, and stellate cells embedded in abundant myxoid stroma that comprised more than 80% of the tumor mass.
  • Chemotherapy and immunotherapy were administered as suggested by an oncologist.
  • The patient died from distant metastases 6 months after the diagnosis.
  • Although some authors believe that myxoid changes do not seem to alter the behavior of melanoma, it remains an important differential diagnosis issue.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Lymph Nodes / pathology. Melanoma / secondary. Phototherapy / methods. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Staging. Risk Assessment. Time Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360128.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ishii N, Yonese J, Tsukamoto T, Maezawa T, Fukui I, Ishikawa Y, Aoki N: [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2002 Jul;93(5):642-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple synchronous primary malignant tumors of fibrosarcoma and squamous cell carcinoma in the urinary bladder: a case report].
  • A 65-year-old housewife presented with a diagnosis of malignant spindle cell tumor of the bladder which had been diagnosed by work up for chance hematuria.
  • Urine cytology revealed a small number of squamous epithelial cells showing dyskeratosis but no spindle cells.
  • Computed tomography and magnetic resonance images showed a markedly enhanced mass, 4 cm in diameter, on the anterior wall of the urinary bladder, which appeared to be adhesive to the pubic bone.
  • Although the anterior wall of the urinary bladder was mildly adhesive to the pubic bone, the surgical margin was negative for malignant cells.
  • The tumor corresponded to a fibrosarcoma that infiltrated the adipose tissue surrounding the urinary bladder.
  • The entire mucosa of the bladder showed diffuse squamous metaplasia, and well differentiated squamous cell carcinoma with pearl formation was found in part.
  • These two malignant tumors were clearly apart from each other, resulting in the histologic diagnosis of synchronous multiple malignant tumors of the bladder.
  • The patient developed a local relapse and pulmonary metastasis of fibrosarcoma one month postoperatively and died two month later without any response to chemotherapy (CYVADIC) and radiotherapy.
  • The current case seems to be the first one in Japan (third in the world) of a patient with multiple synchronous primary malignant tumors, carcinoma and sarcoma, airsing in the urinary bladder.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fibrosarcoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Fibrosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12174642.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 12
  •  go-up   go-down


26. Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM: Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br; 2000 Jan;82(1):55-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience in the treatment of dedifferentiated chondrosarcoma.
  • Dedifferentiated chondrosarcoma is a rare, highly malignant variant of chondrosarcoma in which a high-grade spindle-cell sarcoma coexists with a lower-grade chondroid tumour.
  • We have reviewed our experience with this neoplasm in 22 patients, all of whom were treated using modern oncological principles of planned resection and chemotherapy.
  • Those patients who received chemotherapy, and in whom wide margins of excision were achieved at operation, did best.
  • It is essential to have an accurate preoperative diagnosis in order to plan treatment which may offer a better prospect of cure.
  • [MeSH-major] Bone Neoplasms / therapy. Chondrosarcoma / therapy

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10697315.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


27. Silver SA, Devouassoux-Shisheboran M, Mezzetti TP, Tavassoli FA: Mesonephric adenocarcinomas of the uterine cervix: a study of 11 cases with immunohistochemical findings. Am J Surg Pathol; 2001 Mar;25(3):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the clinicopathologic and immunohistochemical features of 11 examples of this neoplasm, which occurred in women between the ages of 35 and 72 years (mean, 52 years).
  • Microscopically, the carcinomas showed various morphologies, most commonly a small tubular pattern or a ductal pattern resembling endometrioid adenocarcinoma; one tumor had an associated malignant spindle cell component.
  • In a patient with stage IB disease, a mediastinal metastasis and a malignant pleural effusion developed 5.6 years after diagnosis, and the patient died of disease at 6.2 years.
  • Another patient with stage IB disease and a positive vaginal cuff margin that recurred locally after 1.7 years received chemotherapy and was alive and clinically free of disease at 2.5 years.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / diagnosis. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Survival Rate


28. Orui H, Yamakawa M, Ishikawa A, Tsuchiya T, Ogino T: Malignant intramuscular forearm tumor with overwhelming squamous element. Pathol Int; 2000 Jul;50(7):574-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant intramuscular forearm tumor with overwhelming squamous element.
  • Squamous cell carcinoma (SCC) arising in the skeletal muscle is rare.
  • A case of a 19-year-old female patient with an intramuscular forearm tumor showing a histopathologically overwhelming squamous element is presented.
  • Microscopic examination revealed the classical features of SCC, including horn pearls, individual cell keratinization and intercellular bridge.
  • A malignant spindle cell component was not detected.
  • Neither evidence of another primary site nor skin lesion over the tumor was found and no metastatic lesion was detected in the 5 years since the appearance of the mass.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Muscle Neoplasms / pathology
  • [MeSH-minor] Actins / analysis. Actins / genetics. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Therapy, Combination. Female. Forearm / pathology. Humans. Lymph Node Excision. Lymph Nodes / surgery. Magnetic Resonance Imaging. Mitomycin / administration & dosage. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Peplomycin / administration & dosage. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10886743.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Actins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SYT-SSX fusion protein; 50SG953SK6 / Mitomycin; 56H9L80NIZ / Peplomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. Morawietz L, Kuhnen C, Katenkamp D, Le Coutre P, Ladhoff A, Petersen I: Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma. Virchows Arch; 2005 Dec;447(6):990-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma.
  • Myofibrosarcoma is a rare neoplasm that occurs mainly in the head and neck region and extremities of middle-aged patients.
  • We report the case of a 47-year-old male patient with a malignant mesenchymal pulmonary tumor affecting almost the entire lower left lobe.
  • Clinically suggestive for a lung carcinoma, the tumor showed typical features of a myofibrosarcoma.
  • A major spindle cell component was observed being positive for smooth-muscle actin, calponin, and vimentin, while stainings for desmin, h-caldesmon, alkaline phosphatase (ALK), and extensively studied cytokeratins were negative.
  • DNA cytometry revealed aneuploidy with a peak in the near triploid range.
  • Shortly after resection of the primary tumor, the patient showed multiple distant metastases in the contralateral lung, the mediastinal lymph nodes, the left adrenal gland, and the pectoral and deltoid muscle, which responded well to chemotherapy.
  • The case report will discuss the evidence for the final diagnosis of a primary pulmonary myofibrosarcoma and the differential diagnosis of sarcomatoid tumors of the lung.
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Nucleic Acid Hybridization. Pneumonectomy. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1095-8 [8892598.001]
  • [Cites] Pathologe. 2003 Mar;24(2):128-35 [12673503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):219-28 [11176071.001]
  • [Cites] J Dermatol. 2001 Jul;28(7):383-7 [11510507.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):331-40 [8085557.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12 ):1501-7 [11717539.001]
  • [Cites] Ultrastruct Pathol. 1993 Nov-Dec;17(6):611-22 [8122327.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Aug;137(1):33-42 [12377411.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:75-82 [10095420.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):459-69 [11905413.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):393-4; author reply 394-6 [11981942.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):489-96 [9130998.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):535-42 [534390.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):215-23 [15173943.001]
  • (PMID = 16158184.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


30. Oueslati Z, Ben Miled M, Hammoud M, Touati S, Lachkham A, Gamoudi A, Mokni N, El Benna F, Boussen H, El May A, Ladgham A: [Sarcomatoid carcinomas of the upper airways]. Rev Laryngol Otol Rhinol (Bord); 2008;129(3):191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinomes sarcomatoïdes des voies aéro-digestives supérieures.
  • INTRODUCTION: The sarcomatoid carcinoma of the superior aerodigestive tracts is a rare malignant tumour which presents diagnostic and therapeutic challenges.
  • MATERIAL AND METHOD: We report 11 cases of spindle cell carcinomas of the upper airways.
  • Nine patients were smokers and 4 presented with a history of radiation exposure.
  • Histological diagnosis in 3 cases required the use of immunohistochemical studies.
  • This left 9 patients and among them 7 received a curative treatment: 5 by surgery alone, 1 by surgery and radiotherapy, 1 by radiotherapy, 1 by chemo-radiotherapy for the nasopharyngeal lesion and 1 by chemotherapy alone.
  • Two patients died from their disease before treatment.
  • Its diagnosis benefits from progresses in immunohistochemistry, but also from advances in the field of molecular biology.
  • Its treatment and natural evolution remain controversial.
  • [MeSH-major] Carcinoma / diagnosis. Otorhinolaryngologic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Radiation-Induced / mortality. Neoplasms, Radiation-Induced / pathology. Neoplasms, Radiation-Induced / therapy. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Retrospective Studies. Smoking / adverse effects. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694162.001).
  • [ISSN] 0035-1334
  • [Journal-full-title] Revue de laryngologie - otologie - rhinologie
  • [ISO-abbreviation] Rev Laryngol Otol Rhinol (Bord)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-Kelly E, Rubin BP: Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. Int J Gynecol Pathol; 2006 Jul;25(3):288-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumor (GIST) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.
  • Because of their malignant potential and recent advances in the management of GISTs with imatinib mesylate (Gleevec, Glivec), it is imperative that these tumors are correctly diagnosed.
  • All 3 lesions had a spindle cell morphology that mimicked a smooth muscle tumor.
  • The first tumor recurred at 2 years and the second tumor recurred at 10 years; the third case is too recent for meaningful follow-up.
  • Misdiagnosis may lead to inappropriate therapy because conventional chemotherapy and radiotherapy are not effective in the treatment of GISTs, whereas imatinib mesylate (Gleevec, Glivec) has a proven role in managing these tumors.
  • Thus, it is imperative to consider EGISTs in the differential diagnosis of mesenchymal neoplasms in the vulvovaginal/rectovaginal septum.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Rectal Neoplasms / diagnosis. Vaginal Neoplasms / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Benzamides. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Leiomyoma / chemistry. Leiomyoma / diagnosis. Leiomyoma / genetics. Leiomyoma / pathology. Leiomyosarcoma / chemistry. Leiomyosarcoma / diagnosis. Leiomyosarcoma / genetics. Leiomyosarcoma / pathology. Middle Aged. Mutation / genetics. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / analysis. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810068.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / DNA, Neoplasm; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


32. Lifschitz O, Ziv-Sokolovsky N, Ben-Aharon U: [Acute rectal bleeding from malignant stromal tumor]. Harefuah; 2002 Dec;141(12):1019-20, 1092
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute rectal bleeding from malignant stromal tumor].
  • A case report of a 61 years old female admitted with acute bleeding due to malignant stromal tumor of the rectum is described.
  • Preoperative assessments revealed a large tumor located in the rectal wall with extension to the adjacent tissues.
  • The histologic features of needle biopsy was compatible with gastrointestinal stromal tumor.
  • The definitive histological examination showed a gastrointestinal stromal tumor (GISTs), spindle cell type with mucosal invasion, vast necrosis and highly mitotic activity.
  • The tumor cells coexpressed CD34 and smooth muscle actin and were negative for staining desmin and S-100 protein.
  • Adjuvant chemotherapy was given.
  • We decided to describe a rare malignant stromal tumor of the rectum with uncommon clinical presentation.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery
  • [MeSH-minor] Antigens, CD34 / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12534196.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


33. Chen HJ, Xu M, Zhang L, Zhang YK, Wang GM: [Prostate sarcoma: a report of 14 cases]. Zhonghua Nan Ke Xue; 2005 Sep;11(9):683-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To discuss the diagnosis and effective treatment of prostate sarcoma.
  • RESULTS: Prostate sarcoma accounted for 3.21% of all the prostatic malignant tumors treated in our hospital during that period.
  • Pathological test revealed: 7 cases leiomyosarcoma, 1 case rhabdomyosarcoma, 4 cases fibrosarcoma, 2 cases spindle cell sarcoma.
  • All the patients received surgery, chemotherapy and/or radiotherapy.
  • One case failed to be followed up, 11 died 2 approximately 12 months after diagnosis.
  • DRE test may suggest prostate sarcoma but needle biopsy contributes to a definite diagnosis.
  • The prognosis of prostate sarcoma is very poor and the main treatment is surgery followed by chemotherapy and/or radiotherapy.
  • [MeSH-major] Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis


34. Zmonarski SC, Boratyńska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M: Kaposi's sarcoma in renal transplant recipients. Ann Transplant; 2005;10(2):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a spindle-shaped vascular cell tumor that occurs in the skin, lymphoid, respiratory and gastrointestinal tissues.
  • It may resemble aggressive malignant neoplasm in HIV-related or in post-transplant types but classic form may behave as benign, potentially controllable and reversible hyperplasia.
  • KS occurrence is associated with: type and dose of immunosuppression, chronic stimulation by foreign allograft antigens, viral infections (Herpes virus 8), anti rejection and induction therapy, etc.
  • Histological picture shows networks of spindle shaped cells and vascular spaces surrounded by an endothelial cell layer.
  • There is no uniform schema of KS treatment in renal transplant recipients.
  • After conversion to MMF regression of KS was observed, although low therapeutic MMF doses seem to be appropriate.
  • Sirolimus seems to inhibit the growth of established vascularized tumors and this effect is best realized with relatively low immunosuppressive doses of drug.


35. Craver RD, Lipscomb JT, Suskind D, Velez MC: Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components. Ann Diagn Pathol; 2001 Oct;5(5):285-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components.
  • A 15-year-old black girl had a near total resection of a malignant thyroid teratoma with bilateral nodal involvement and mediastinal extension.
  • A malignant spindle cell component stained for smooth-muscle actin, muscle actin, and to a lesser extent S-100.
  • Loose myxoid tissue resembled primitive cartilage.
  • The tumor from the left and right thyroid lobes exhibited trisomy 8, the right also had hyperdiploid cell lines.
  • She was treated with aggressive combination chemotherapy and radiation.
  • Presently there is no residual disease 16 months after diagnosis.
  • Malignant thyroid teratoma is an aggressive tumor, with 15 of 27 reported patients dying 2 weeks to 3 years after diagnosis.
  • Survivors have been treated with total or subtotal resection, combination chemotherapy with agents effective in the treatment of germ cell tumors as well as sarcomas, and radiation for either recurrent or residual disease.
  • The heterologous elements, lacking MIC2 staining and t(11;22), support the diagnosis of malignant teratoma rather than a neuroepithelial tumor.
  • Trisomy 8 is the first cytogenetic abnormality described in malignant thyroid teratoma.
  • Therapy should be tailored to the management of all transformed histologies.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma / diagnosis. Teratoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Aneuploidy. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Image Cytometry. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11598856.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 34
  •  go-up   go-down






Advertisement